Fact-checked by Grok 2 weeks ago

Utilization management

Utilization management (UM) is a systematic approach in healthcare administration that employs prospective, concurrent, and reviews to assess the medical necessity, appropriateness, efficiency, and quality of services, with the primary aims of curbing overuse of resources, minimizing costs, and promoting clinically justified . Emerging during the mid-20th century, UM initially focused on audits of stays to address unnecessary admissions and lengths of stay, but it proliferated in the and as employers, insurers, and policymakers responded to escalating healthcare expenditures by implementing techniques. The core processes include , which evaluates planned interventions before they occur to prevent avoidable procedures; concurrent review, which monitors ongoing for timely discharge; and analysis, which examines completed services for compliance with evidence-based standards. In practice, UM is conducted by insurers, health plans, or third-party organizations using criteria derived from clinical guidelines, often involving nurses, physicians, or automated tools to approve, deny, or modify requests, thereby influencing in and capitated systems alike. Proponents credit UM with substantial reductions in utilization and cost savings—such as through length-of-stay controls that have historically lowered expenses—while fostering adherence to best practices. However, UM has drawn persistent criticism for eroding physician autonomy, imposing administrative burdens that exacerbate (with surveys indicating up to 93% of physicians affected), and potentially delaying or denying essential care through overly restrictive criteria or appeals processes, which can incur high denial reversal rates and harm risks. These tensions underscore UM's dual role as a tool for fiscal discipline amid causal drivers like in but also a for debates over balancing economic incentives against uncompromised clinical judgment.

Definition and Core Principles

Definition and Scope

Utilization management (UM) refers to a systematic set of processes employed by health insurers, organizations, and healthcare providers to evaluate the medical necessity, appropriateness, and efficiency of healthcare services prior to, during, or after delivery. These techniques aim to ensure that care is medically necessary, delivered in the most suitable setting, and aligned with evidence-based standards, thereby balancing access to services with resource stewardship. Originally evolving from utilization review practices focused on stays, UM has broadened to encompass , behavioral health, and [long-term care](/page/Long-term care) services across public and private health plans. The scope of UM includes prospective review (e.g., for elective procedures or high-cost interventions), concurrent review (monitoring ongoing inpatient or outpatient care to assess continued need), and retrospective review (post-service audits to verify billing accuracy and service justification). It applies to a wide array of stakeholders, including physicians, nurses, and case managers who apply clinical criteria—often derived from guidelines like those from the or Care Guidelines—to decisions on coverage approvals, denials, or alternatives such as step therapy or site-of-service changes. In practice, UM operates within frameworks to mitigate overutilization, which data from the indicate can account for up to 30% of unnecessary healthcare expenditures in models, while promoting outcomes like reduced length of stay without compromising . UM's implementation varies by payer type, with and programs mandating UM components like precertification for certain services to curb , waste, and abuse, as outlined in federal regulations under 42 CFR Part 456. Private insurers extend this to network adequacy and appeals processes, ensuring decisions are timely (e.g., within 72 hours for urgent cases per NCQA standards) and evidence-driven, though scope limitations exclude emergency services exempt from prior approval to avoid delays in . Overall, UM's purview emphasizes causal links between service utilization and health outcomes, prioritizing interventions supported by randomized controlled trials or meta-analyses over anecdotal provider requests.

Underlying Rationale from First Principles

Utilization management arises from the recognition that healthcare resources, including personnel, facilities, and funding, are inherently scarce, necessitating mechanisms to allocate them toward interventions that demonstrably improve patient outcomes while minimizing waste and potential harm. In payment models, which predominate in many systems, providers receive compensation proportional to the volume of services rendered, creating financial incentives for overutilization, such as ordering superfluous tests or extending stays unnecessarily. Estimates indicate that 10-30% of procedures, admissions, and diagnostic tests may lack medical necessity under such incentives, diverting resources from higher-value care and inflating overall expenditures without commensurate health benefits. Empirical observations of substantial variations in healthcare utilization—both geographic and practitioner-specific—further underscore the need for , as these disparities often reflect inconsistent practices rather than differences in underlying patient needs or illness severity. For instance, analyses of data reveal that 40-50% of utilization variation stems from patient demand factors, with the remainder attributable to local supply-side influences like provider density or practice norms, implying inefficiencies amenable to . Such variations, documented across regions with up to twofold differences in procedure rates for comparable populations, signal opportunities for to curb low-value care that consumes resources without enhancing survival or . At its core, the rationale emphasizes causal : medical services must possess of , where the anticipated benefits outweigh risks and costs, grounded in the principle that unproven or marginally beneficial interventions represent opportunity costs that could otherwise fund proven therapies for others. By prospectively evaluating medical necessity against clinical guidelines and outcomes data, utilization management promotes a framework where resource deployment aligns with verifiable improvements in health, averting both underutilization of effective treatments and the harms from , such as iatrogenic complications. This approach, while rooted in cost containment amid escalating expenditures—such as U.S. healthcare outlays rising from $234 billion in 1982 to $500 billion by 1987—prioritizes systemic efficiency to sustain access for broader populations.

Methods and Implementation

Types of Utilization Review

Utilization review in healthcare is primarily divided into three temporal categories: prospective, concurrent, and , each designed to assess the medical necessity, appropriateness, and efficiency of services at different stages of care delivery. These distinctions enable payers, providers, and regulators to balance cost control with , drawing on evidence-based criteria such as InterQual or guidelines. Prospective review occurs prior to the delivery of services, often involving precertification or preauthorization for admissions, elective procedures, or high-cost interventions like . This type evaluates proposed treatments against clinical standards to determine coverage eligibility and prevent unnecessary utilization from the outset; for instance, a request for joint replacement surgery might require submission of patient history, diagnostic , and rationale, with decisions typically rendered within 3-5 business days for standard cases or 72 hours for urgent ones under regulations like those from the (). Delays in prospective approval can impact patient access, though proponents argue it averts overutilization, with studies indicating it reduces inappropriate admissions by up to 20-30% in settings. Concurrent review takes place during active treatment, such as stays or ongoing therapies, where reviewers monitor progress through daily assessments, reviews, or interdisciplinary rounds to confirm continued medical necessity and explore alternatives like discharge planning. This real-time oversight, often conducted by nurses or physicians via telephonic or on-site evaluation, aims to shorten lengths of stay—averaging reductions of 1-2 days in per data—while mitigating risks of prolonged hospitalization without clear justification. For example, in a admitted for , concurrent review might approve initial days but deny extensions if stabilize and outpatient antibiotics suffice, thereby promoting evidence-based transitions to lower-intensity care. Retrospective review is performed after services have been rendered, analyzing claims, medical records, and outcomes post-discharge to verify , accuracy, and adherence to standards, often as part of audits or appeals processes. This approach identifies patterns of overutilization for future interventions, such as denying reimbursement for non-essential tests; data from payers show it recovers 5-10% of expenditures deemed unjustified, though it risks provider disputes since care cannot be altered retroactively. In contexts, retrospective audits by Audit Contractors have flagged billions in improper payments annually since 2009, emphasizing its role in detection despite criticisms of administrative burden. While less proactive than other types, it informs systemic improvements by aggregating outcome data across populations.

Criteria, Guidelines, and Evidence-Based Standards

Utilization management relies on standardized criteria sets to assess medical necessity, defined as services that are reasonable, necessary, and appropriate for the or treatment of illness or injury, consistent with generally accepted professional medical standards, and not primarily for convenience or experimental purposes. The two predominant criteria systems in the United States are InterQual, developed by , and (formerly Care Guidelines), which provide structured algorithms for evaluating inpatient admissions, length of stay, and outpatient procedures across specialties. These sets incorporate patient-specific factors such as age, principal , comorbidities, functional status, results, and response to prior treatments to determine the appropriate level of care, often categorizing services into inpatient, observation, or outpatient based on severity of illness, intensity of service, and discharge potential. Development of these criteria emphasizes evidence-based standards, drawing from peer-reviewed clinical literature, randomized controlled trials, meta-analyses, and consensus guidelines from professional societies like the or . InterQual criteria are reviewed and updated at least annually to integrate emerging and changes in clinical practice, while MCG aligns with Institute of Medicine principles for trustworthy guidelines, including transparency in methodology, conflict-of-interest management, and explicit linkages to supporting . Payers and providers must also comply with regulatory benchmarks, such as those from the (CMS), which require medical necessity determinations to reflect national coverage determinations and avoid coverage for services lacking sufficient of efficacy. Accreditation bodies like the (NCQA) and Utilization Review Accreditation Commission (URAC) mandate the use of objective, -based criteria in utilization management processes to ensure decisions prioritize clinical outcomes over cost alone, with requirements for timely review of denials and appeals grounded in documented . For instance, NCQA standards require organizations to apply criteria that are relevant, current, and validated against clinical data, facilitating prospective, concurrent, and retrospective reviews while minimizing variability in determinations. Despite their widespread adoption, these tools face scrutiny for potential over-reliance on algorithmic rigidity, prompting calls for integration of individualized clinical judgment to address gaps in for rare conditions or novel therapies.

Roles of Reviewers and Stakeholders

Reviewers in utilization management primarily consist of nurses and physicians who evaluate the medical necessity, appropriateness, and of healthcare services using evidence-based clinical criteria and national standards. nurses conduct prospective pre-admission certifications, concurrent onsite or telephonic monitoring of admissions and length-of-stay, and claims reviews, collecting and interpreting data to determine alignment with guidelines for hospital-level or specific treatments. Physicians, often serving as advisors or in peer-review capacities, handle escalated cases involving denials or high-cost interventions, engaging in physician-to-physician discussions—comprising 25-50% of their time—to assess clinical rationale, ensure compliance, and overturn or uphold initial determinations based on guidelines. This interdisciplinary between nurses, physicians, and sometimes pharmacists emphasizes communication to balance cost containment with quality outcomes. Stakeholders include payers, healthcare providers, patients, and regulators, each contributing to the oversight and execution of UM processes. Payers such as health insurers or employers direct UM programs through contracted organizations, assessing certifications to curb unnecessary utilization—estimated at 10-30% of services—and achieve savings like 4.5-8% in costs via reduced bed days. Providers submit clinical documentation to justify requests, interact daily with reviewers to defend care plans, and leverage UM data for internal quality enhancements, while filing appeals against denials to advocate for patient needs. Patients, though often indirectly engaged, bear the consequences of UM decisions, including potential financial for non-certified private-sector care, and hold rights—frequently pursued via providers or advocates—to challenge adverse determinations and secure access to disputed services. Regulators provide ethical and legal oversight, mandating transparent criteria, mechanisms, and with standards to prevent overly restrictive practices that could undermine care access.

Timing and Processes in Care Delivery

Utilization management incorporates reviews at three primary stages aligned with care delivery: prospective, concurrent, and . Prospective review evaluates proposed services before they are rendered, typically through processes to assess medical necessity and appropriateness against evidence-based criteria. This stage aims to prevent unnecessary utilization by requiring approval for elective procedures, inpatient admissions, or high-cost interventions, such as surgeries or , often within 5 to 14 business days depending on urgency. For emergent cases where pre-review is infeasible, initial assessment may occur within 24 to 72 hours post-admission. Concurrent review occurs during active treatment, such as stays, to monitor ongoing resource use, length of stay, and progress toward . Reviewers, often nurses or physicians, conduct daily assessments using standardized guidelines like InterQual or Care Guidelines to justify continued care, authorize extensions, or initiate . This oversight integrates with care teams to adjust plans, reducing prolonged stays; for instance, decisions on day-of-review extensions must typically be communicated promptly to avoid disruptions. In organizations, concurrent processes may involve telephonic or electronic case management to coordinate multidisciplinary input. Retrospective review examines services after delivery, focusing on claims auditing to verify , coding accuracy, and adherence to policies for decisions. This post-hoc analysis identifies overutilization patterns or denials, often within 30 to 60 days of claim submission, and supports quality improvement by aggregating data across episodes. Appeals for adverse determinations at any stage follow structured timelines, such as 72 hours for expedited reviews, with consultations required for denials involving clinical judgment. Across stages, processes emphasize timely notifications to providers and patients, with criteria updated annually to reflect current evidence.

Historical Evolution

Origins in Cost Containment

Utilization review, the precursor to modern utilization management, emerged in the as a primarily aimed at curtailing excessive lengths of stay and unnecessary admissions, which were identified as key drivers of escalating healthcare expenditures in the model. This approach involved post-hoc audits by committees to assess the medical necessity of services already rendered, reflecting early recognition that provider incentives under traditional indemnity encouraged overutilization without accountability for resource efficiency. By the early , these efforts formalized further in response to surging spending, which reached 5.9% of GDP by amid limited coverage and unregulated provider decisions. The enactment of and in 1965 intensified cost pressures, as enrollment exploded and hospital expenditures doubled between 1965 and 1970, prompting federal mandates for utilization review committees in participating hospitals to evaluate admission necessity and ongoing care appropriateness. These requirements, embedded in the Social Security Amendments, sought to mitigate from third-party payment, where patients and providers faced minimal financial disincentives for excess services, leading to average hospital stays exceeding clinical needs. Empirical data from the period showed inpatient days rising sharply post-1965, underscoring the causal link between expanded coverage without utilization controls and unchecked cost growth. In the , cost containment evolved through the creation of Professional Standards Review Organizations (PSROs) via the 1972 Social Security Amendments, which extended to outpatient and ambulatory settings under , targeting overutilization by physicians through standardized criteria and external oversight. PSROs represented a shift toward prospective elements, such as preadmission certification, as federal spending on hospital insurance climbed 18% annually in the early , fueled by inflationary pressures and service intensity absent . Private insurers began adopting similar retrospective and limited prospective reviews even earlier, driven by employer concerns over benefits costs equating to rising shares of labor compensation, laying groundwork for utilization management as a systemic tool against inefficient . These origins emphasized empirical of service patterns over trust in unchecked professional discretion, establishing cost containment as the foundational rationale amid evidence of supplier-induced demand inflating expenditures.

Growth During Managed Care Expansion

The expansion of managed care organizations (MCOs) in the United States during the 1980s and 1990s propelled the widespread adoption of utilization management (UM) as a core mechanism for controlling healthcare costs amid rising expenditures driven by fee-for-service incentives. Health maintenance organization (HMO) enrollment surged from approximately 12 million in 1982 to 80 million by 1999, while preferred provider organization (PPO) participation grew from negligible levels in the early 1980s to over 110 million enrollees in the same period. This shift reflected employer and insurer responses to healthcare inflation, which had pushed national health expenditures from 8.9% of GDP in 1980 to higher levels by the decade's end, with UM techniques like prior authorization and concurrent review becoming standard to mitigate overutilization. By the mid-1990s, managed care covered a majority of employer-sponsored insurance, reaching 51% of such enrollees by 1993, and Medicaid managed care enrollment climbed from 10% in 1990 to 55% by 1999. UM programs evolved from retrospective hospital reviews of the 1950s and 1960s into prospective and concurrent strategies integral to MCO operations, with maturation accelerating in the 1980s as perceptions solidified that unnecessary services accounted for significant cost growth. By 1990, approximately 80% of private insurers mandated utilization review for high-cost services such as hospitalizations and surgical procedures, a sharp increase from earlier decades when such oversight was limited primarily to inpatient settings. HMO-driven UM facilitated practice pattern changes, including a marked shift from inpatient to outpatient care, which contributed to slower national health expenditure growth in the mid- to late 1990s compared to prior periods. Enrollment in managed care plans grew over 10% annually starting in the mid-1980s, embedding UM as a foundational tool that integrated evidence-based criteria to assess medical necessity and reduce variance in provider decisions. This period's UM proliferation was evidenced by its application across major service lines, with comprehensive management of , outpatient, and ancillary services yielding measurable reductions in utilization rates when implemented rigorously. managed care enrollment saw its most rapid increase in the middle to late , aligning with broader strategies that leveraged UM to balance access and fiscal discipline amid the "managed care revolution." These developments underscored UM's role in addressing risks inherent in indemnity insurance, though retrospective analyses later debated the sustainability of such controls as consumer backlash prompted a partial retreat from strict models by the early .

Adaptations in Response to Healthcare Reforms

Following the enactment of the (ACA) on March 23, 2010, utilization management (UM) programs adapted by emphasizing prospective and concurrent reviews over retrospective ones to support emerging value-based payment models and accountable care organizations (ACOs). The ACA's promotion of ACOs, which hold providers financially accountable for care coordination, integrated UM into efforts to reduce hospital readmissions and post-acute care overuse, such as through proactive discharge planning and evidence-based transitions to lower-cost settings. This shift addressed incentives for volume by aligning UM criteria with quality metrics, including the Hospital Readmissions Reduction Program, which penalizes excess readmissions starting in 2012. The Medicare Access and CHIP Reauthorization Act (MACRA) of 2015 further influenced UM adaptations by introducing the Merit-based Incentive Payment System () and advanced alternative payment models (APMs), rewarding clinicians for lower-cost, higher-quality care. UM processes evolved to incorporate and clinical guidelines that support MIPS reporting on utilization patterns, such as reduced inpatient stays and increased efficiency, to avoid payment adjustments that began affecting reimbursements in 2019 based on 2017 performance. In value-based care frameworks spurred by these reforms, UM transitioned from denial-focused strategies to collaborative tools, like predictive modeling for optimal care pathways, helping providers meet shared savings targets in ACOs where 53.4% of traditional beneficiaries were aligned by January 2025. Recent (CMS) reforms, including the 2024 Interoperability and Final Rule (effective in phases through 2027), have prompted UM adaptations toward electronic prior authorization (ePA) via and faster decision timelines—72 hours for expedited requests starting in 2026—to minimize delays while maintaining safeguards against overutilization. These changes, alongside state-level restrictions on out-of-state reviewers and "gold carding" exemptions for high-compliance providers, leverage for automated approvals with clinician oversight, reducing administrative burdens but requiring UM vendors to enhance data for real-time eligibility checks. Such adaptations balance access improvements under the ACA's legacy with ongoing cost-containment, as evidenced by UM's role in aligning with value-based objectives like holistic outcome tracking in chief medical officer-led programs.

Empirical Evidence of Effectiveness

Demonstrated Cost Savings

Utilization management interventions, including and concurrent , have yielded measurable cost reductions in targeted areas such as hospital admissions, inpatient days, and high-cost services. A of hospital-based strategies found that 23 studies reported overall cost savings, with utilization programs reducing blood product utilization by 38.8% for and 31.4% for platelets, alongside savings from cancelled unnecessary orders. Case management approaches similarly decreased inpatient admissions by 38%, hospital days by 36%, and visits by 30%, lowering associated charges. Early implementations in private sector programs demonstrated substantial efficiencies. For instance, Deere & Company's utilization review led to a 21% reduction in inpatient days over 36 months, generating $11 in savings per dollar invested in the program. Blue Cross of North Carolina's pilot achieved a 37% drop in days, while Blue Cross of reported a 23% decrease in days and $30 million in savings over five months. Comparative analyses, such as RCA's, showed benefit costs declining by 4% under managed utilization versus a 6% increase in unmanaged groups. In public programs, curtailed real inpatient expenditure growth to 1.4% annually, compared to 6.5% without such controls. Aetna's program reduced hospital admission rates by 8%, yielding gross savings of approximately 12% over six quarters. Multivariate studies, including Feldstein et al., quantified reductions of 13% in admissions, 11% in inpatient days, and 6% in total expenditures from 1984 to 1986. Prior authorization on specific services has also produced targeted savings. demonstrations reduced expenditures on power mobility devices from $12 million to $3 million monthly across seven states in 2012, and by $5.33 million over 13 months for non-emergent hyperbaric oxygen therapy from 2015 to 2018. Step therapy for specialty drugs lowered insurer costs by 9% to 11%. These outcomes reflect controls on moral hazard-driven overutilization, though net system-wide savings may vary due to administrative burdens and potential shifts in care patterns.

Impacts on Care Quality and Patient Outcomes

Utilization management seeks to improve care quality by ensuring services align with evidence-based standards, potentially reducing inappropriate treatments that could harm patients. For instance, requirements prevent the use of medications in contraindicated populations, such as in patients with , thereby avoiding severe adverse events, and restrict off-label prescribing unless supported by peer-reviewed literature or compendia like AHFS-DI. In programs, dosage limits and step therapy in state initiatives have decreased misuse and overdose deaths—17,000 in 2017—by curbing duplicative therapies, demonstrating outcome benefits in high-risk scenarios. However, prior authorization and other restrictions frequently lead to treatment delays and abandonments, adversely affecting adherence, persistence, and clinical outcomes. Meta-analyses indicate that such measures prompt patients to forgo prescriptions due to delays, with 90% of physicians reporting worse patient outcomes and 24% observing serious adverse events, including increased asthma exacerbations from postponed therapies. Providers often switch to alternative medications in over 36% of cases or avoid newer agents in 75%, reducing treatment persistence and leading to suboptimal care, such as higher risks of discontinuation for antipsychotics. Empirical studies on specific conditions yield mixed results, underscoring causal uncertainties in downstream effects. In , quantity limits on antibiotics for marginally raised probability by 0.75 percentage points per 10% exposure increase (p=0.061) among 147,526 cases, though showed no significant impact; for urinary tract infections in 632,407 cases, neither tool affected hospitalization or events. Broader reviews confirm cost reductions in targeted areas like specialty drugs (9-11% via step therapy) but note unclear net health impacts, with delays contributing to care avoidance and potential shifts to costlier interventions like visits, without definitive evidence of overall quality gains. These findings highlight that while utilization management mitigates overutilization risks, implementation frictions often erode benefits, particularly in urgent or care contexts where timely access is critical.

Key Studies and Quantitative Analyses

A of hospital utilization management strategies, encompassing interventions such as utilization review, discharge planning, and care coordination, analyzed 92 studies and identified 23 with cost-related outcomes, of which six reported net savings following implementation of utilization review programs. These included reductions in hospital charges across 10 studies and emergency department costs in two others, attributed to mechanisms like pre-admission screening and concurrent review that curtailed unnecessary inpatient stays. Quantitative evaluations of private-sector utilization programs documented an 8% reduction in days and 6-8% savings in total healthcare costs, based on analyses of employer-sponsored plans. Onsite concurrent s yielded additional 6% reductions in bed days and 9% net cost savings per episode. In organizations, admission rates averaged 2-3%, correlating with longitudinal declines in overall admissions over seven years, though causal attribution requires controlling for concurrent reforms. Specific trials highlighted targeted impacts: Sweeney et al. (2007) reported that patient-centered utilization management reduced admissions by 38%, days by 36%, and emergency visits by 30%, without evidence of shortened lifespan or worsened outcomes. Koehler et al. (2017) found care bundles in high-risk elderly patients lowered 30-day readmission and emergency visit rates through coordinated discharge planning. Pre-admission reviews decreased elective admissions by approximately 12% in one . A of 29 case management interventions, a core component of utilization management, classified six as both more effective and less costly than comparators, including one with €17.61 per-patient savings in care; 18 others improved outcomes at incremental costs below $50,000 per in seven cases, indicating favorable efficiency in chronic disease settings. These findings underscore utilization management's role in mitigating overutilization, with reductions in length of stay (e.g., 0.33 additional days via physician profiling) and readmissions, though aggregate effects vary by intensity and .

Criticisms and Counterarguments

Allegations of Care Denials and Delays

Critics of utilization management, particularly processes, allege that these mechanisms frequently result in unwarranted denials or significant delays in approving medically necessary care, potentially harming patient outcomes. Physicians surveyed by the in 2024 reported that 79% of prior authorization delays or denials at least sometimes compelled patients to pay out of pocket, with 34% indicating such issues led to serious adverse events including hospitalization, permanent injury, or death. Similarly, a 2023 Federation of American Hospitals analysis found that 89% of hospital leaders observed prior authorizations negatively impacting patient outcomes, including fatalities in some instances. Empirical data highlight elevated denial rates linked to utilization review. In Medicare Advantage plans, initial claim denial rates reached 17% in analyses from 2020 onward, with 57% of those denials ultimately overturned upon appeal, suggesting potential overreach in initial assessments. For skilled nursing facility care, UnitedHealthcare's denial rate surged ninefold from 1.4% in 2019 to higher levels by 2023, per a 2024 Senate report, raising concerns about systematic barriers to post-acute services. Overall healthcare claim denials averaged 11.8% in 2024, up from prior years, with commercial and Medicare Advantage plans contributing disproportionately. Delays from prior authorizations exacerbate these issues, with studies documenting treatment abandonment and compromised continuity. A 2025 review indicated that 94% of patients faced care delays due to prior authorizations, while 78% discontinued treatment entirely. In home agency contexts, interviews revealed consistent patterns of delayed and worsened outcomes attributable to authorization hurdles. Specialty care, such as therapies, has seen repeated rejections delaying critical interventions, as evidenced by 2024 case patterns. Allegations extend to algorithmic tools and third-party reviewers, with investigations uncovering insurers' reliance on vendors like EviCore, whose denial facilitation has prompted scrutiny for prioritizing cost control over clinical judgment. reporting in 2024 also documented insurers continuing to employ physicians whose denial decisions were repeatedly overturned in court, violating protections under the No Surprises Act. Patient surveys underscore access barriers, with KFF from 2023 showing insurance-related denials or delays directly causing forgone needed in affected populations. Procedural prescription denials correlated with heightened utilization and net spending increases, per a 2025 , implying that initial refusals drive costlier downstream interventions. These claims, often from provider and sources, contrast with insurer defenses but persist amid litigation trends alleging wrongful denials in and treatment contexts.

Administrative and Provider Burdens

Utilization management processes, particularly s, impose substantial administrative burdens on healthcare providers and their staff, requiring extensive documentation, submissions, and follow-ups to justify treatments deemed medically necessary. Physicians and practice staff collectively spend an average of 13 to 14 hours per week handling requests, equivalent to nearly two full workdays, which diverts time from direct patient care. In a 2024 survey of over 1,000 physicians, 40% reported employing dedicated staff exclusively for managing these authorizations, highlighting the scale of needed. These burdens extend to utilization review paperwork, where nearly half of physicians dedicate 0 to 5 hours weekly, but many exceed this, contributing to inefficiencies in operations. A 2022 study on drug utilization management found that physicians and administrators frequently encounter delays and denials, necessitating repeated appeals that amplify time costs without proportional improvements in approval rates. Such administrative demands increase operational expenses for s, as staff hours are consumed by insurer interactions rather than clinical activities, potentially raising overall healthcare delivery costs. On the provider side, utilization management erodes clinical and fosters by interposing insurer decisions between physicians and , often overriding professional judgment on care appropriateness. A November 2024 survey published in the American Journal of Managed Care revealed that 93% of physicians experiencing attributed it in part to utilization management, with most agreeing it negatively affects relationships and decisions. This friction leads to moral distress, as providers navigate rigid protocols that prioritize containment over individualized care, exacerbating workload and reducing . Empirical data from reports indicate that these processes delay necessary interventions, further straining provider efficiency and contributing to higher turnover rates in specialties reliant on frequent authorizations, such as and .

Rebuttals Based on Moral Hazard and Overutilization Risks

Critics of utilization management often highlight risks of care denials and administrative burdens, yet proponents rebut these concerns by emphasizing the pervasive inherent in , where coverage insulates patients and providers from full costs, incentivizing excessive service use. Empirical studies consistently demonstrate this effect: the RAND Health Insurance Experiment (1974–1982) found that individuals with free care at the point of service utilized approximately 40% more outpatient services than those facing cost-sharing, without commensurate health improvements, underscoring how insurance distorts consumption toward overutilization. Similarly, a 2017 NBER analysis reviewed decades of data showing insured individuals consume substantially more care when out-of-pocket prices are low, with elasticities indicating 10–30% reductions in utilization from modest copayments, confirming as a driver of inefficient spending rather than patient need. Without utilization management tools like , amplifies overutilization risks, particularly from provider-induced demand and patient behaviors unmoored from cost realities. Research from public hospital settings in (2024) revealed insured patients opting for costlier treatments over equivalents due to zero perceived expense, leading to elevated expenditures and resource strain. A Booth synthesis (2024) of real-world data further illustrates that generous coverage renders healthcare "too cheap," prompting overuse of low-value services like unnecessary or hospitalizations, which collectively inflate U.S. spending by hundreds of billions annually without enhancing outcomes. Proponents argue that isolated denial cases pale against systemic waste: unchecked could balloon costs 20–50% higher, per elasticity estimates, eroding insurer solvency and premium affordability for all. These rebuttals frame utilization management not as a barrier but as a necessary , ensuring reviews target marginal, low-benefit services while preserving access to essential care. Systematic reviews of demand-side interventions (2022) identify utilization controls as effective in curbing consumer , reducing frivolous claims without broad access erosion, as evidenced by stable utilization rates post-implementation in controlled systems. Critics' focus on delays ignores causal evidence that absent such safeguards, overutilization fosters dependency on high-cost interventions, perpetuating a cycle of fiscal unsustainability; for instance, ex ante studies in show preventive overuse preceding acute escalations, which utilization management preempts. Thus, the risks of underutilization via rigorous review are outweighed by the empirically documented perils of coverage, prioritizing long-term resource stewardship over short-term convenience.

Federal and State Oversight

At the federal level, the exercises primary oversight over utilization management (UM) in government-sponsored programs, enforcing requirements through regulations under Title 42 of the . For plans, CMS mandates that UM processes adhere to traditional coverage criteria, prohibiting plans from applying more restrictive standards, as established in the 2024 Contract Year Final Rule (CMS-4201-F) effective January 1, 2024. This rule also requires plans to submit annual UM data for transparency and subjects them to program audits where reviewers evaluate denied requests for compliance. In managed care, 42 CFR Part 456 prescribes utilization control measures, including statewide programs for reviewing institutional services and drug use, with CMS monitoring state compliance via the and CHIP Managed Care Monitoring and Oversight Initiative. Hospitals participating in must maintain a utilization review () plan under 42 CFR § 482.30, which evaluates the medical necessity of services to prevent overutilization, with committees reviewing at least 5% of extended stays or high-cost cases monthly. enforces these through surveys, audits, and corrective actions, with recent expansions including a June 27, 2025, initiative targeting wasteful services in Original via enhanced reviews. Federal oversight extends to processes, requiring timely decisions—typically within 72 hours for expedited requests—and appeals rights, amid concerns over delays in approvals documented in 2023 audits showing variability in denial rates across plans. States regulate UM for commercial and supplemental Medicaid administration, primarily through departments of insurance, with 40 states mandating or licensure for entities conducting utilization to ensure independence and expertise. The (NAIC) Utilization Review Model Act (Model 73), adopted or adapted by many states, sets standards for timely reviews, qualified reviewers, and written criteria based on evidence-based guidelines, prohibiting financial incentives tied to denial rates. State laws vary in stringency; for instance, Health and Safety Code § 1374.721 requires UM decisions to incorporate individual clinical history over algorithmic group data, reinforced by a November 2024 law limiting AI solely to support, not supplant, licensed judgments in medical necessity determinations. Oversight mechanisms include state-mandated reporting of denial rates, external appeals processes, and penalties for non-compliance, such as fines or license revocation, with compendiums revealing that 48 states define "medical necessity" in statutes to guide UM, often prioritizing peer-reviewed evidence over proprietary insurer policies. In contexts, states like enforce UM via dedicated regulations under the Division of Workers' Compensation, requiring prospective, concurrent, and retrospective reviews within strict timelines (e.g., 14 days for standard requests). Federal-state interplay occurs in , where states must align with rules but may impose additional safeguards, such as independent external reviews, to address overutilization risks while balancing cost controls.

Appeals Mechanisms and Denial Processes

In utilization management, denial processes typically begin with an initial review by the insurer or organization to assess medical necessity, coverage criteria, or policy compliance, resulting in an adverse benefit determination that withholds, reduces, or terminates for services. Insurers must provide written notification of s, including specific reasons, denial codes, reference to plan provisions, and appeal rights, often within 30 days for standard requests or 72 hours for expedited cases involving urgent care, as mandated by federal regulations under the (ACA) and implementing rules from the Departments of Health and Human Services (HHS), Labor (DOL), and Treasury. These s frequently target high-cost procedures, inpatient stays, or , with plans issuing nearly 50 million requests in 2023, of which about 6% were initially denied. Internal appeals form the first level of redress, requiring plans to establish full and fair review procedures independent of the initial decision-maker, allowing submission of additional evidence within 180 days of denial in most cases. Under ERISA for employer-sponsored plans (29 CFR § 2560.503-1), claimants receive a decision within 60 days for standard appeals or 72 hours for urgent ones, with protections against conflicts of interest in reviewer selection. State laws, such as New York Insurance Law § 4904, similarly mandate written or telephonic filing options and timely resolutions, often extending to provider-initiated appeals with enrollee consent. Empirical data indicate high overturn rates at this stage; for instance, 83.2% of prior authorization appeals succeed upon internal review, suggesting initial denials may sometimes exceed strict evidence-based thresholds for necessity. If internal appeals fail, external review provides an independent assessment by accredited entities, required under ACA standards for non-grandfathered plans (45 CFR § 147.136). Eligible denials—typically those involving medical judgment—undergo state-administered processes in 50 states plus , or the federal process in the 18 states lacking equivalent programs, with requests filed within four months of the final internal denial. Reviewers, often physicians in the relevant specialty, must decide within 45-60 days, binding on the plan, and expanded post-2022 to cover rescissions and certain non-medical denials. Success rates vary by program; in , about 63.9% of appeals for supplies succeed at external levels, while overall prior authorization overturns exceed 80% across payers, highlighting potential over-denial in utilization controls to mitigate . For managed care, denial rates reached 12.5% in sampled plans as of 2023, with appeals serving as a check against administrative overreach. Regulatory oversight ensures procedural safeguards, including of in denial letters and prohibitions on retaliatory practices, though varies; the NAIC's influences state standards for timely notifications and appeals tracking. Litigation risks arise from flawed processes, such as inadequate explanations or biased , but precedents emphasize adherence to timelines and evidence standards over substantive second-guessing of clinical judgment. Providers and patients face administrative burdens in compiling records, yet these mechanisms empirically curb unwarranted while preserving insurer incentives against overutilization. Litigation over utilization management practices, particularly claim denials stemming from prior authorizations and algorithmic reviews, has intensified since 2020, driven by documented rises in denial rates across commercial and plans. Insurers denied approximately 17% of initial claims in recent analyses, with post-acute care denials doubling from 10.9% to 22.7% between 2020 and 2022, often attributed to automated tools prioritizing cost containment over clinical evidence. This surge has fueled class actions and individual suits alleging breaches of fiduciary duty under the Employee Retirement Income Security Act (ERISA), where plaintiffs argue that denials systematically override recommendations and deviate from plan terms or medical standards. Federal courts have increasingly scrutinized the use of proprietary algorithms in utilization decisions, with cases highlighting potential conflicts of interest when tools developed by or for insurers automate denials. In a 2023 against , plaintiffs contended that the company's nH Predict software wrongfully denied skilled nursing and rehabilitation services to Medicare Advantage enrollees by applying rigid, cost-based thresholds that ignored individual medical needs, prompting federal judges to reject motions limiting discovery and allow broader evidentiary probes into algorithmic opacity. Similarly, a parallel suit against alleged misuse of the same tool for premature discharges, reflecting a trend where over 15 reports and multiple lawsuits since 2023 target major insurers for substituting data-driven predictions for clinical judgment, potentially violating ERISA's requirement for decisions "solely in the interest of participants." Precedents under ERISA emphasize that utilization review must adhere to objective, evidence-based criteria rather than insurer-imposed efficiencies. The landmark Wit v. United Behavioral Health (2019) established that health plans cannot enforce internal guidelines deviating from generally accepted standards of care, as the U.S. District Court for the Northern District of California found United Behavioral Health liable for denying claims based on flawed "Level of Care" policies that emphasized acute symptoms and cost targets over management, breaching ERISA obligations. The Ninth Circuit partially affirmed this in 2023, reinforcing that plans must justify denials with plan-specific rationale and external clinical benchmarks, a extending beyond behavioral health to broader utilization disputes. Courts apply a deferential "abuse of discretion" review if plans grant administrators discretion, but review otherwise, as clarified in Ariana M. v. Humana Health Plan of (2018), where the Fifth Circuit mandated uniform scrutiny to prevent arbitrary denials. ERISA preemption has limited state-level challenges to utilization practices, shielding insurers from tort claims like or in review processes, as seen in cases like Danca v. Private Health Care Systems affirming federal uniformity over varying state standards. However, ongoing litigation trends signal evolving judicial tolerance for probing algorithmic biases, with 2024-2025 cases increasingly invoking ERISA's provisions to demand in denial rationales, potentially curbing overreliance on black-box tools absent rigorous validation against outcomes . While some denials withstand review when aligned with plan language, precedents underscore that utilization management cannot substitute financial incentives for causal evidence of medical necessity, prompting insurers to refine processes amid heightened legal exposure.

Contemporary Developments and Future Outlook

Technological and Data-Driven Innovations

(AI) and (ML) algorithms have enabled automation of routine (PA) decisions in utilization management, reducing manual review times from days to seconds in some implementations. For example, ML models analyze clinical against payer policies to approve low-risk requests instantaneously, with one national insurer reporting PA processing speeds increased by a factor of 1,400 through such tools. Platforms like Cohere Health's UM Suite apply AI to automate up to 90% of PAs, incorporating to extract and match to evidence-based guidelines while flagging complex cases for human review. These systems prioritize causal factors such as history, , and cost-effectiveness metrics derived from large datasets, aiming to minimize delays without compromising medical necessity assessments. Predictive analytics, powered by big data integration from electronic health records and claims databases, facilitate proactive utilization forecasting and risk stratification. Vendors employ to detect patterns of potential overutilization, such as unnecessary or admissions, enabling interventions like targeted for providers. A Chilmark case study of Xsolis's Dragonfly platform with a national health showed measurable reductions in administrative burdens and improved decision consistency through AI-driven utilization review. The (CMS) launched the WISeR Model in October 2025, partnering with technology firms to deploy advanced analytics that identify and curtail clinically unsupported services, projecting savings from decreased wasteful spending. Despite efficiency gains, adoption in utilization management has prompted scrutiny over algorithmic biases and . The (AMA) surveyed physicians in 2025, finding over 60% believed unregulated contributed to systematic denials of necessary by overly rigid policy application. Regulatory efforts, including state-level mandates for explainability in as of 2024, seek to address these by requiring auditable decision pathways and bias audits. KPMG's 2025 analysis emphasizes that validated , when combined with human oversight, enhances causal accuracy in UM by leveraging empirical outcome data over anecdotal reviews, though full realization depends on interoperable data standards.

Recent Policy Reforms and Industry Shifts

In 2023, the () issued the Interoperability and Final Rule (CMS-0057-F), mandating that payers implement for electronic submissions by July 1, 2027, and requiring decisions on expedited requests within 72 hours and standard requests within seven days starting January 1, 2026, to streamline utilization management processes while enhancing . This rule also compels plans to report aggregate data annually, including denial rates and appeal outcomes, with public disclosure on plan websites to address concerns over opaque denial practices. Building on these, announced a six-year model for traditional fee-for-service on July 1, 2025, targeting services prone to fraud and low-value care, such as certain , to curb wasteful spending without broadly restricting access. State-level reforms have complemented federal efforts, with over a dozen states enacting laws in the first half of 2025 to bolster market oversight, including restrictions on payer utilization management tactics like excessive s for high-cost procedures. For instance, legislative pushes in 2025 have aimed to limit administrative burdens on providers, reflecting against perceived overreach in cost-control measures. Concurrently, insurers have responded with voluntary reductions; UnitedHealthcare pledged a 10% cut in services requiring effective 2025, prioritizing low-risk procedures to mitigate provider and delays. Industry shifts emphasize technological integration and value-based models to refine utilization management. Adoption of for decision support in prior authorizations has accelerated since , though regulatory scrutiny has intensified, with states and federal agencies proposing oversight to prevent algorithmic biases in denial rates. The U.S. utilization management solutions market, valued at $613 million in , is projected to grow at a 9.9% CAGR through 2030, driven by demand for automated, data-driven tools that balance cost containment with evidence-based approvals. Health plans increasingly incorporate value-based care frameworks, using utilization data to incentivize outcomes over volume, as evidenced by 2025 trends linking reduced low-value interventions to sustained cost savings amid rising overall utilization post-pandemic. These adaptations address criticisms of traditional UM's inefficiencies, fostering hybrid models that prioritize causal links between interventions and patient outcomes over rote administrative hurdles.

Prospects for Balancing Efficiency and Access

Emerging technological innovations, particularly (AI) and , offer prospects for streamlining utilization management (UM) processes to minimize delays while preserving cost controls against overutilization. AI-powered systems can automate low-risk prior authorizations (PAs), enabling real-time decisions that reduce processing times by up to 10 days in some implementations, thereby enhancing patient access without compromising reviews for high-risk cases. For instance, generative AI and models analyze patient data against evidence-based criteria, potentially achieving 10% efficiency gains across the estimated 500 million annual U.S. UM reviews, saving tens to hundreds of millions in operational costs. However, outcomes depend on regulatory oversight; the (CMS) 2024 Interoperability and Prior Authorization Final Rule prohibits sole reliance on AI for denials to prevent erroneous rejections, addressing concerns that unregulated tools may systematically deny necessary care in over 60% of physician-reported cases. Policy reforms, such as "gold carding" programs, further promise to balance efficiency and access by exempting high-performing providers from routine PAs. These initiatives, adopted by insurers like UnitedHealthcare and Humana in 2025, grant exemptions to clinicians with approval rates exceeding 90%, reducing administrative burdens that consume up to 30% of providers' weekly time while maintaining scrutiny for outlier cases. By 2025, programs like Highmark's have expanded to over 25,000 clinicians, fostering trust in evidence-based practice patterns and aligning with state-level reforms in over a dozen jurisdictions that mandate such exemptions for 80-90% approval thresholds. Complementary trends include electronic medical record (EMR) integration and data-driven silo-breaking via standardized metrics, as promoted by the National Committee for Quality Assurance (NCQA), which through 2025 accreditation updates enables 93% of PAs to close within 48 hours and improves oversight of delegated activities. Shifts toward value-based care models and member-centered UM hold additional potential to reconcile efficiency with access by incentivizing proactive resource use over reactive denials. Alternative payment models like bundled payments reduce volume for aligned providers, emphasizing outcomes such as reduced emergency visits through in programs like cancer care engagement. These approaches, supported by mandates for faster timelines, could mitigate burnout and care delays—evident in 30% of procedures requiring authorization—provided implementations prioritize empirical guidelines over cost-centric biases. Overall, while challenges like technological biases persist, integrated reforms leveraging , exemptions, and data analytics signal viable paths to curb moral hazard-driven overuse without unduly restricting medically necessary services, contingent on rigorous validation of decision accuracy.

References

  1. [1]
    Utilization Management - StatPearls - NCBI Bookshelf - NIH
    The goal is to ensure the delivery of efficient and effective health care, to reduce the misuse of inpatient services, and to promote high quality and safe ...Definition/Introduction · Issues of Concern · Nursing, Allied Health, and...
  2. [2]
    Utilization Management: Introduction and Definitions - NCBI - NIH
    In this report, the committee considers utilization management as a set of techniques used by or on behalf of purchasers of health care benefits to manage ...
  3. [3]
    Origins of Utilization Management - Controlling Costs ... - NCBI - NIH
    Beginning in 1979, General Motors started joint labor-management efforts to monitor the cost-containment activities of participating Blue Cross plans, implement ...Early Cost-Management... · Other Factors Giving Rise to...
  4. [4]
    The Utilization Management Industry: Structure and Process
    The backgrounds of the organizations and their founders includes HMOs, PSROs, the insurance industry, claims administration, employee benefit management, ...
  5. [5]
  6. [6]
  7. [7]
    Utilization management: issues, effects, and future prospects
    Utilization management encompasses a diverse set of activities designed to influence the use of health care services and thereby constrain health care resource ...
  8. [8]
    Utilization management negatively impacts physician well-being ...
    Nov 13, 2024 · Utilization management significantly contributes to physician burnout, affecting treatment decisions and patient relationships, with 93% of ...
  9. [9]
    [PDF] Utilization Management as a Cost-Containment Strategy - CMS
    (A brief description of the major UM programs and the history of UM can be found in the Technical note.) Individual program utilization and costs. Inpatient ...
  10. [10]
    Utilization Management Accreditation - NCQA
    Utilization management helps ensure that patients have the proper care and the required services without overusing resources. NCQA Utilization Management ...Standards · FAQs · Process - UMCR - Other · Current Customers
  11. [11]
    [PDF] VHA DIRECTIVE 1117 Veterans Health Administration ... - VA.gov
    Oct 15, 2020 · a. The UM Program, a key component of VHA's quality management system, provides vital tools for managing quality and resource utilization.
  12. [12]
    Utilization Management Accreditation FAQs - NCQA
    Utilization Management Accreditation is for organizations that provide full-scope utilization management services.Missing: insurance | Show results with:insurance
  13. [13]
    The Case Against Fee-for-Service Health Care - Third Way
    Sep 9, 2021 · Fundamentally, fee-for-service rewards volume and high prices over quality. While the vast majority of medical doctors work every day to make ...
  14. [14]
    The Impact of Fee-For-Service Medical Billing on Healthcare ...
    Apr 29, 2024 · FFS incentivizes providers to perform more services, which can lead to overutilization of healthcare resources. Providers may conduct ...
  15. [15]
    Sources of Geographic Variation in Health Care: Evidence from ...
    Dec 24, 2014 · We find that 40-50 percent of geographic variation in utilization is attributable to patient demand, with the remainder due to place-specific ...
  16. [16]
    SOURCES OF GEOGRAPHIC VARIATION IN HEALTH CARE
    We study the drivers of geographic variation in US health care utilization, using an empirical strategy that exploits migration of Medicare patients.
  17. [17]
    How Utilization Review Works - Verywell Health
    Nov 17, 2024 · Utilization review is a process designed to ensure that medical care is effective, efficient, and in line with evidence-based standards of care.
  18. [18]
    Utilization Reviews: An Introduction - AGS Health
    Jun 27, 2023 · ... . Types of Utilization Reviews. There are several different types of utilization review including: Precertification, Concurrent Review ...
  19. [19]
    9792.6. Utilization Review Standards - Definitions
    (u) “Utilization review process” means utilization management functions that prospectively, retrospectively, or concurrently review and approve, modify, delay, ...
  20. [20]
    Understanding Prospective, Concurrent, And Retrospective Reviews
    Jan 18, 2024 · Prospective coding review is a process intended to help physicians prepare for upcoming patient encounters.
  21. [21]
    What does 'retrospective review' mean in terms of UR? - daisyBill
    Feb 24, 2020 · A retrospective review is any UR conducted after medical services have been provided and for which approval has not already been given.
  22. [22]
    Procedures for conducting prospective, concurrent and retrospective ...
    Prospective reviews include the initial review conducted prior to the start of treatment, and the initial review for treatment to a different body part.
  23. [23]
    The Utilization Review Process and the Origins of Medical Necessity
    Jun 21, 2018 · Utilization review, as a process, was introduced in the 1960s to reduce overutilization of resources and identify waste. The utilization review ...
  24. [24]
    InterQual v. MCG vs. the Deep Blue Sea - RACmonitor
    A deep-dive look into the role and relevance of two national standards for guiding a hospital's utilization and denial management efforts.
  25. [25]
    What You Need to Know About the Utilization Review Process
    Jun 5, 2020 · Acute inpatient hospitals use Milliman and InterQual criteria to help determine the appropriateness of care. Both sets of criteria are evidence ...
  26. [26]
    A Remote Nurse's Guide to MCG and InterQual
    Apr 24, 2023 · MCG criteria are typically regarded as more simplistic and user-friendly, while InterQual is a bit more thorough. Treating providers have ...Missing: sets | Show results with:sets
  27. [27]
    [PDF] Utilization Management Criteria - VA Vendor Portal
    Jan 1, 2018 · InterQual® Criteria sets are reviewed and updated at least annually to reflect current evidence-based practice and changes in healthcare ...
  28. [28]
    The Value of Independent Clinical Guidelines - MCG Health
    Jan 23, 2024 · MCG clinical experts explore the IOM standards set forth to develop trustworthy clinical guidelines and how MCG meets those standards.
  29. [29]
    42 CFR 482.30 -- Condition of participation: Utilization review. - eCFR
    The committee must review professional services provided, to determine medical necessity and to promote the most efficient use of available health facilities ...
  30. [30]
    [PDF] Utilization Management – Clinical Criteria and Availability of Clinical ...
    The criteria must comply with Medicare, local and national coverage determinations, and relevant Medicaid requirements. Approved Clinical Criteria for ...
  31. [31]
    Health Utilization Management Accreditation - URAC
    URAC's accreditation program assures the clinical and operational soundness of your health utilization management process.
  32. [32]
    Standards - UMCR - Other - NCQA
    The standards are designed for organizations providing full-scope utilization management services that include the use of evidence-based criteria, relevant ...
  33. [33]
    A Typical Day as a Utilization Management Doctor
    Jun 9, 2025 · Peer to Peer Reviews: Most UM physicians say they spend about 25-50% of their time on the phone with other clinicians (not all of whom are ...
  34. [34]
    Succeeding as a Physician in Utilization Review - Medical Economics
    Apr 8, 2019 · This role has also been described as physician advisor, chart review, or peer review among other titles specific to various companies.
  35. [35]
    [PDF] Prior Authorization and Utilization Management Reform Principles
    Many utilization review entities employ step therapy protocols, under which patients are required to first try and fail certain therapies before qualifying for ...
  36. [36]
    What is Healthcare Utilization Management? - Xsolis
    Utilization management is an integral part of how insurance companies, or health plans, assess clinical treatment decisions and coordinate patient care.
  37. [37]
    Utilization Review Process: What You Need to Know
    Utilization Management criteria and clinical policies are reviewed at least annually and updated as appropriate, with the involvement from physicians who are a ...
  38. [38]
    [PDF] A Brief History of Utilization Management (UM) - APTA Private Practice
    Utilization management has been employed in some form for decades. Retrospective UM first surfaced in the 1950s in an effort to reduce unnecessary hospital ...
  39. [39]
    [PDF] History of Health Spending in the United States, 1960-2013 - CMS
    Nov 19, 2015 · In the 1960s and early 1970s, health expenditure growth was dominated by non-price factors, as expanded health insurance coverage and increased ...
  40. [40]
    Markets at Risk— Current and Future Challenges in a Managed ...
    Nov 30, 2000 · HMO enrollment grew from about 12 million to 80 million from 1982-99 and PPO participation shot up from virtually nil in the early 1980s to 110 ...
  41. [41]
    Managed Care: What Went Wrong? Can It Be Fixed?
    When combined with rapidly expanding technology, these incentives led national health expenditures to increase rapidly through the 1980s, from 8.9% of GDP in ...Missing: statistics | Show results with:statistics
  42. [42]
    A Brief History of Managed Medical Care in the USA
    May 6, 2024 · By 1993, a majority (51%) of Americans receiving health insurance through their employers were enrolled in managed health care plans.
  43. [43]
    Medicaid Reform in the 1990s - PMC - NIH
    The percentage of Medicaid eligibles in managed care increased from approximately 10 percent in 1990 to 55 percent in 1999, of which 42 percent were enrolled ...Missing: utilization statistics
  44. [44]
    Managed Care - ScienceDirect.com
    Utilization review is particularly common for high cost services, such as hospitalizations and surgical procedures. About 80% of insurers in 1990 required that ...
  45. [45]
    [PDF] A History of Managed Health Care and Health Insurance in the ...
    Sep 3, 2015 · * Utilization review, the encouragement of second opinions, and large case management all entailed at times questioning physicians' medical judg ...
  46. [46]
    Milestones in Medicare Managed Care - PMC - NIH
    The greatest growth in Medicare managed care enrollment occurred in the middle to late 1990s, coinciding with the “managed care revolution.”
  47. [47]
    The End of an Era: What Became of the “Managed Care Revolution ...
    With managed care in retreat, hospitals improved their position considerably between 1998–1999 and 2000–2001, securing better contract terms from health plans ...
  48. [48]
    Accountable Care Organization - StatPearls - NCBI Bookshelf - NIH
    Accountable Care Organizations place financial responsibility on providers in hopes of improving patient management and decreasing unnecessary expenditures ...
  49. [49]
    Accountable Care Organizations Are Transforming the Management ...
    ACOs have the potential to affect post-acute care through: 1) proactive management of the hospital discharge process to prevent complications and readmissions, ...
  50. [50]
    The Impact of the Payment and Delivery System Reforms of the ...
    Apr 28, 2022 · These initiatives transformed health care delivery and payment across the United States, and many have reduced costs and improved quality of care.
  51. [51]
    MACRA: MIPS & APMs - CMS
    Sep 10, 2024 · Changes the way that Medicare rewards clinicians for value over volume; Streamlines multiple quality programs under the new Merit Based ...<|separator|>
  52. [52]
    Four Years into MACRA: What has Changed? - PMC - NIH
    The first year's performance results for MIPS eligible clinicians had 95% of clinicians meeting neutral or positive adjustment thresholds.
  53. [53]
    CMS Moves Closer to Accountable Care Goals with 2025 ACO ...
    Jan 15, 2025 · As of January 2025, 53.4% of people with Traditional (fee-for-service) Medicare are in an accountable care relationship with a provider.Missing: utilization management ACA
  54. [54]
    Why Does Value-Based Care Matter in Utilization Management?
    Nov 12, 2024 · Value-based care improves patient outcomes and manages costs, shifting focus to quality and efficiency, and has significant implications for  ...
  55. [55]
    CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F)
    Sep 10, 2025 · This final rule also focuses on efforts to improve prior authorization processes through policies and technology, to help ensure that patients ...
  56. [56]
    The health care utilization management landscape | Evernorth
    Regulatory pressures and technological advancements are changing utilization management as we know it—here's what plan sponsors should know.
  57. [57]
    Finalized regulations look to phase out manual prior authorization
    Aug 6, 2025 · “It is hard to imagine that these [prior authorization] changes would lead to a reduction in utilization management tools,” Wurzburg said.
  58. [58]
    [PDF] UM Evolution - Health Plan Adaptations Rolling into 2025 - HealthHelp
    CMOs are focusing on aligning UM practices with value-based objectives, emphasizing quality outcomes and cost-effectiveness. This shift requires a more holistic ...
  59. [59]
    Strategies for utilisation management of hospital services
    May 23, 2022 · Twenty three studies that evaluated costs, reported cost savings in the hospitals. Conclusions. Utilisation management interventions can ...Missing: empirical peer-
  60. [60]
    Impact of Prior Review Programs - Controlling Costs and ... - NCBI
    The percentage increase in expenditures for groups with prior review was lower than the rate of medical inflation, whereas the opposite was true for comparison ...Missing: quantitative | Show results with:quantitative
  61. [61]
    [PDF] IMPACTS OF PRIOR AUTHORIZATION ON HEALTH CARE COSTS ...
    This brief summarizes the use of prior authorization policies for coverage of health care goods and services and reviews the evidence on cost and quality ...Missing: quantitative | Show results with:quantitative
  62. [62]
    Benefits of Prior Authorizations - PMC - NIH
    Prior authorizations can be used to manage prescription drug costs, they may also improve patient outcomes by ensuring appropriate use and minimizing harmful ...
  63. [63]
    Influence of Prior Authorization Requirements on Provider Clinical ...
    However, meta-analyses have found that PA and other formulary restrictions can adversely influence medication adherence, clinical outcomes, and treatment ...
  64. [64]
    Effects of utilization management on health outcomes - NIH
    In this paper, we test for adverse effects of utilization management in the Medicare Part D program using two common acute clinical conditions—urinary tract ...
  65. [65]
    Utilization management as a cost-containment strategy - PMC - NIH
    Likewise at the system level, UM programs are associated with a significant reduction in the rate of increase in hospital costs during the 1980s (Schwartz and ...
  66. [66]
    Cost-effectiveness of Case Management: A Systematic Review - AJMC
    Jul 19, 2022 · This systematic review found that studies of case management interventions have adequate quality and, in many cases, show cost-effective or even cost-saving ...
  67. [67]
    Prior authorization delays care—and increases health care costs
    Aug 12, 2024 · Among the physicians surveyed, 79% said that a prior authorization delay or denial at least sometimes leads to a patient paying out of pocket ...Missing: evidence | Show results with:evidence
  68. [68]
    How Insurers' Use of Prior Authorization Harms Patients - FAH
    Apr 13, 2023 · 89% report prior authorization had a negative impact on patient outcomes – sometimes even leading to death. Effects of additional administrative ...
  69. [69]
    Medicare Advantage Denies 17 Percent Of Initial Claims
    Jun 2, 2025 · Our study found claim denial rates of 17 percent as a share of initial claim submissions. We also found that 57 percent of all claim denials were ultimately ...Missing: allegations wrongful review<|control11|><|separator|>
  70. [70]
    Analysis: Senate Report on MA Plans Reveals 'Troubling Data'
    Oct 26, 2024 · In addition, UHC's denial rate for skilled nursing facility care increased by a factor of nine, from an initial denial rate of 1.4% (3,016 ...Missing: studies | Show results with:studies
  71. [71]
    Denial Rates Are Climbing: What Healthcare Revenue Cycle ...
    Jun 10, 2025 · Initial claim denials hit 11.8% in 2024—up from 10.2% just a few years earlier. Commercial and Medicare Advantage Plans Are a Big Factor Denials ...Missing: utilization 2020-2025
  72. [72]
    Prior Authorizations and the Adverse Impact on Continuity of Care
    Apr 2, 2025 · Prior authorizations result in 94% of patients experiencing delays in care and 78% abandoning treatment altogether. Prior authorizations create ...
  73. [73]
    Prior authorization and utilization management for post-acute home ...
    Interviews with HHA representatives revealed that prior authorization delays care, compromises access, and affects patient outcomes, aligning with prior ...
  74. [74]
    Research Shows Prior Authorization Denials Delay Critical ...
    May 10, 2024 · A pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
  75. [75]
    'Not medically necessary': Inside the company helping America's ...
    Nov 7, 2024 · Insurers do not make explicit demands for more denials, a former EviCore sales executive said, Instead, they asked about “controlling the ...
  76. [76]
    Insurers Continue to Rely on Doctors Whose Judgments Have Been ...
    Dec 30, 2024 · In dozens of court cases, ProPublica found, judges ruled that insurance companies had violated a federal law meant to protect people who get ...
  77. [77]
    Consumer Problems with Prior Authorization: Evidence from KFF ...
    Sep 29, 2023 · The survey asked people whether their insurance problems directly resulted in adverse outcomes such as delayed or denied access to needed care, ...Missing: utilization management
  78. [78]
    Procedural Prescription Denials and Risk of Acute Care Utilization ...
    Jan 30, 2025 · This cross-sectional study examines the association between procedural prescription denials and net spending through downstream acute care utilization among ...
  79. [79]
    What Are Your Rights If Your Mental Health Or Addiction Treatment ...
    ... claims have been wrongfully denied by your insurance company. An attorney will be able to assess your case and advise you of your potential causes of action ...
  80. [80]
    Don't fall for these myths on prior authorization
    Apr 17, 2025 · Physicians and their staff spend an average of 13 hours completing those requests each week. 40% of physicians have staff who work exclusively ...
  81. [81]
    Prior authorization: How it evolved, why it burdens physicians and ...
    Apr 24, 2025 · Physicians now spend nearly two full workdays each week wrangling prior authorizations. The American Medical Association's 2024 survey found ...
  82. [82]
    A Guide to Relieving Administrative Burden: Prior Authorization - AAFP
    On average, physicians and practice staff spend about two days per week (14 hours) completing PAs. In March 2023, the Medical Group Management Association (MGMA) ...<|separator|>
  83. [83]
    Utilization Management and Physician Burnout - AJMC
    Nov 8, 2024 · This survey assesses physician experiences with utilization management and burnout and investigates whether there is a link between them.<|separator|>
  84. [84]
    The Physician and Administrator-Reported Cost of Drug Utilization ...
    Jul 23, 2022 · The aim of this study was to assess physician and practice administrator experiences with drug utilization management.
  85. [85]
    Utilization Management Negatively Impact Physicians and Patient ...
    Feb 4, 2025 · Of the physicians who reported experiencing burnout, 93 percent said utilization management was a contributing factor. Sponsored Recommendations ...Missing: efficiency | Show results with:efficiency
  86. [86]
    The Health Insurance Experiment: A Classic RAND Study Speaks to ...
    Dec 6, 2006 · In a large-scale, multiyear experiment, participants who paid for a share of their health care used fewer health services than a comparison ...Missing: overutilization | Show results with:overutilization
  87. [87]
    Moral Hazard in Health Insurance: What We Know and How We ...
    Nov 22, 2017 · This work has produced compelling evidence that moral hazard in health insurance exists – that is, individuals, on average, consume less ...
  88. [88]
    The Impact of Moral Hazard on Healthcare Utilization in Public ...
    Dec 12, 2024 · This behavior leads to the overutilization of medical resources, resulting in higher healthcare system expenditures and increased insurance ...
  89. [89]
    Healthcare and the Moral Hazard Problem | Chicago Booth Review
    Jul 22, 2024 · Next, let's turn to real-world evidence on moral hazard in health insurance. What do copayments do? Health economists first examined moral ...Missing: overutilization | Show results with:overutilization
  90. [90]
    A systematic review of strategies used for controlling consumer ...
    Oct 18, 2022 · This study aimed to determine and analyze the strategies used to control consumer moral hazards in health systems.
  91. [91]
    [PDF] Health Insurance and Ex Ante Moral Hazard: Evidence from Medicare
    While limited, empirical evidence on the extent of ex ante moral hazard in the health insurance context is mostly consistent with these predictions about ...<|control11|><|separator|>
  92. [92]
    [PDF] faqs-related-to-coverage-criteria-and-utilization-management ...
    Feb 6, 2024 · Answer: For Medicare basic benefits, MA organizations must make medical necessity determinations in accordance with all medical necessity ...
  93. [93]
    42 CFR Part 456 -- Utilization Control - eCFR
    This part prescribes requirements concerning control of the utilization of Medicaid services including ... 1) A statewide program of control of the utilization of ...Missing: oversight healthcare
  94. [94]
    Medicaid and CHIP Managed Care Monitoring and Oversight Initiative
    CMS is committed to strengthening the monitoring and oversight of Medicaid and CHIP managed care programs.
  95. [95]
    CMS Launches New Model to Target Wasteful, Inappropriate ...
    Jun 27, 2025 · Under the model, providers and suppliers in the assigned regions will have the choice of submitting prior authorization requests for selected ...
  96. [96]
    Part C Utilization Management (UM) Annual Data Submission - CMS
    Sep 25, 2025 · The purpose of this web page is to increase transparency related to the Part C Utilization Management ("UM") annual data submission.
  97. [97]
    Utilization Review Certification / License | www.harborcompliance.com
    40 states currently require entities to obtain a certification or license before conducting utilization review, and almost every state has regulations.
  98. [98]
    [PDF] MO-73-1 UTILIZATION REVIEW AND BENEFIT DETERMINATION ...
    This Act establishes standards for utilization review and benefit determination processes to manage health care services. It is also known as the Utilization ...
  99. [99]
    California Health and Safety Code § 1374.721 (2024) - Justia Law
    A health care service plan that provides hospital, medical, or surgical coverage shall base any medical necessity determination or the utilization review ...
  100. [100]
    California Limits Health Plan Use of AI in Utilization Management
    Nov 7, 2024 · California's law requires AI to use clinical history, not just group data, and cannot replace licensed physician decisions for medical ...
  101. [101]
    [PDF] State-by-State Compendium of Medical Necessity Regulation - HCFO
    This compendium is a state-by-state guide created by surveying state regulators about their efforts to monitor health plans' medical necessity and coverage ...
  102. [102]
    DWC utilization review - California Department of Industrial Relations
    Utilization review (UR) is a process to review treatment to determine if it is medically necessary, governed by DWC regulations. Employers must have a UR ...
  103. [103]
    [PDF] Guidance and Best Practices Relating to the States' Surveillance ...
    The utilization control requirement is found at 1902(a)(30)(A) and 42 Code of Federal Regulations (CFR) Part 456. With these facts in mind, States have ...
  104. [104]
    [PDF] Internal Claims and Appeals and the External Review Process ...
    Provide notification of internal appeals and external review rights, the plan's or issuer's review procedures, and time limits. ▫ Provide notification about ...<|separator|>
  105. [105]
    Medicare Advantage Insurers Made Nearly 50 Million Prior ... - KFF
    Jan 28, 2025 · Nearly two-thirds (63.9%) of appeals for durable medical equipment, prosthetics, orthotics and other supplies were successful.
  106. [106]
    29 CFR § 2560.503-1 - Claims procedure. - Law.Cornell.Edu
    Every employee benefit plan shall establish and maintain a procedure by which a claimant shall have a reasonable opportunity to appeal an adverse benefit ...Missing: mechanisms | Show results with:mechanisms
  107. [107]
    New York Insurance Law § 4904 (2024) - Appeal of Adverse ...
    (c) A utilization review agent shall establish a standard appeal process which includes procedures for appeals to be filed in writing or by telephone. A ...
  108. [108]
    Over 80% of prior auth appeals succeed. Why aren't there more?
    Oct 3, 2024 · The statistic is particularly alarming when one considers that the overwhelming majority of appeals—83.2%—resulted in the insurance company ...
  109. [109]
    External Review | HealthCare.gov
    There are 2 steps in the external review process: You file an external review: You must file a written request for an external review within four months after ...
  110. [110]
    How to Fight Your Health Insurance Denial With an External Appeal
    Oct 7, 2025 · Under federal rules, third-party review companies typically have between 45 and 60 days to decide the outcome of an external review. You may ask ...
  111. [111]
    New OIG Report Examines Prior Authorization Denials in Medicaid ...
    Jul 27, 2023 · OIG found that Medicaid MCOs had an overall prior authorization denial rate of 12.5%–more than 2 times higher than the Medicare Advantage rate ( ...<|separator|>
  112. [112]
    Insurers' AI Denials of Postacute Care Face Senate Scrutiny | AJMC
    Oct 28, 2024 · From 2020 to 2022, the denial rate for postacute care more than doubled: from 10.9% to 22.7%; this occurred while Humana was working to automate ...<|control11|><|separator|>
  113. [113]
    UnitedHealth lawsuit over AI denials moves forward - BenefitsPRO
    Sep 12, 2025 · A 2023 lawsuit alleged that Humana also used nH Predict to wrongfully deny Medicare Advantage members' claims. Last month, a federal judge ...
  114. [114]
    Judge denies UnitedHealth's bid to limit discovery in AI coverage ...
    Sep 10, 2025 · The plaintiffs allege the tool overrides physicians' decisions and led to premature denials of medically necessary services, forcing families to ...
  115. [115]
    UnitedHealth Group Abuse Tracker
    Fifteen reports and five lawsuits for denying patient care based on cost instead of medical necessity;; Fourteen reports and seven lawsuits for steering ...
  116. [116]
    Court Rules Against UBH in Precedent-Setting Case
    The ruling sets a precedent for plans regulated by the federal mental health parity law by establishing that mental and substance use disorders are chronic ...
  117. [117]
    [PDF] Wit v. United Behavioral Health - Ninth Circuit Court of Appeals
    Aug 22, 2023 · First and foremost, the injury that is the basis of Plaintiffs' claims was the adoption and use of flawed Guidelines in deciding whether.Missing: utilization | Show results with:utilization
  118. [118]
    A Uniform Standard of Review in ERISA Benefit Denial Cases
    Mar 16, 2018 · With its en banc decision in Ariana v. Humana Health Plan of Texas, 1 the Fifth Circuit reconsidered the standard of review in an ERISA denial of benefits case.Missing: key utilization
  119. [119]
    ERISA § 514 Preemption in Utilization Review: Danca v. Private ...
    The court extensively referenced several key precedents to bolster its analysis on ERISA preemption: New York State Conf. of Blue Cross Blue Shield Plans v.
  120. [120]
    The Legal Landscape for AI-Enabled Decisions for Health Care ...
    Jan 30, 2025 · November 14, 2023), the plaintiffs allege UnitedHealth used AI technology to essentially deny patient services. Plaintiffs assert claims of ...
  121. [121]
    Unlocking The Potential Of AI In Prior Authorization - Oliver Wyman
    One large national insurer reported that use of an AI tool made the prior authorization process 1,400 times faster. Machine learning can also aide payers in ...Missing: review | Show results with:review
  122. [122]
    AI-Powered Prior Authorization | Cohere Health® UM Suite
    Cohere's AI-driven platform automates up to 90% of prior authorizations while ensuring compliance with business rules and enhancing clinical quality.
  123. [123]
    AI-driven Utilization Management Solution from Xsolis Delivers Up ...
    Chilmark's utilization management case study with a national health plan found that Xsolis' Dragonfly Platform and Precision UM solutions resulted in ...
  124. [124]
    WISeR (Wasteful and Inappropriate Service Reduction) Model - CMS
    Oct 17, 2025 · Solution: The WISeR Model will help reduce clinically unsupported care by working with companies experienced in using enhanced technologies to ...
  125. [125]
    How AI is leading to more prior authorization denials
    Mar 10, 2025 · Over 60% of doctors say unregulated AI tools systematically deny patients coverage for necessary care. The AMA is fighting to fix prior authorization.Missing: machine learning
  126. [126]
    Regulation of AI in Healthcare Utilization Management and Prior ...
    Oct 31, 2024 · This Holland & Knight alert provides a summary of these efforts to regulate the use of AI in UM and PA, as well as recommendations for key stakeholders.
  127. [127]
    [PDF] The Next Frontier in Utilization Management - KPMG International
    Jul 11, 2025 · Healthcare technology vendors are leveraging AI and automation to enhance administrative efficiency, streamline processes, and improve ...
  128. [128]
    Final Rules on Medicare Advantage Prior Authorization Offer ...
    May 30, 2024 · Payers will now be required to report aggregate information about prior authorizations and to publish that information on their websites.
  129. [129]
    Medicare Program; Implementation of Prior Authorization for Select ...
    Jul 1, 2025 · This notice announces a 6-year model focused on reducing fraud, waste (including low-value care), and abuse in Medicare fee-for-service (FFS)Background · Model Specifications
  130. [130]
    How States Strengthened Their Health Care Markets in the 2025 ...
    Aug 27, 2025 · In the first half of 2025, states enacted numerous laws to strengthen their health care markets. These new laws address several recurring ...
  131. [131]
    Top health policy issues hospitals, payers, docs and tech in 2025
    Feb 12, 2025 · Limiting payers' utilization management tactics. Perhaps smelling blood in the water, hospital groups are among the healthcare provider ...
  132. [132]
    Prior authorization in 2025: What to know - Becker's Payer Issues
    Jun 27, 2025 · UnitedHealthcare has said it will reduce the number of services requiring prior authorization by 10% in 2025.
  133. [133]
    U.S. Utilization Management Solutions Market Report, 2030
    The U.S. utilization management solutions market size was estimated at USD 613.15 million in 2024 and is projected to grow at a CAGR of 9.9% from 2025 to 2030.
  134. [134]
    Healthcare Utilization Trends in 2025: How Health Plans Use Value ...
    Jul 25, 2025 · Value-based care is helping health plans overcome increased utilization challenges with improvements in outcomes, cost savings, and member ...
  135. [135]
  136. [136]
    How the UnitedHealthcare Gold Card program helps modernize ...
    Sep 4, 2025 · The Gold Card program is designed to make the prior authorization process simpler and more streamlined.
  137. [137]
    Humana Accelerates Efforts to Eliminate Prior Authorization ...
    Jul 22, 2025 · Creating a national gold card program for physicians – In 2026, Humana will launch a new gold card program that waives prior authorization ...Missing: carding | Show results with:carding
  138. [138]
    Gold Carding Program - Highmark Provider Resource Center
    Sep 2, 2025 · The Gold Carding program provides expedited prior authorization for clinicians who demonstrate adherence to appropriate clinical criteria.Clinician Roster · Value of Gold Carding · Program Overview
  139. [139]
    Prior Authorization Reform Gains Momentum in States - MultiState
    Aug 14, 2025 · Gold carding instructs insurers to allow providers who have a high (80%-90%) prior authorization approval rate to bypass prior authorization for ...
  140. [140]
    Utilization Management Trends - Carelon.com
    and responding to — with innovative product models, public policy dialogue, and partner engagement.
  141. [141]
    Breaking Down Silos in Utilization Management: A Data-Driven ...
    Sep 11, 2025 · Utilization management is a hot-button issue in the health care industry. Health plans view prior authorization as an essential function ...Missing: controversies criticisms<|separator|>
  142. [142]
    Challenges of Current Utilization Management Systems and the Call ...
    Jun 5, 2025 · Many of today's UM systems instead contribute to patient harm, physician burnout, and operational inefficiencies. With new regulatory reforms and technological ...Missing: controversies criticisms
  143. [143]
    [PDF] The Use and Regulation of AI in Utilization Management
    Nov 14, 2024 · “The primary benefit of using AI for utilization management is the ability to reduce the clerical burden, expedite approvals for patients, and ...